Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | PDE1A | P54750 | 1/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341679 | 0.89 | SMN1; SMN2 (0.54) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5119056 | 0.83 | ESR1 (0.64) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13165099 | 0.82 | PDE5A (0.57) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3340270 | 0.82 | RAB9A (0.52) | PDE5AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29577222 | 0.81 | LMNA (0.53) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5130570 | 0.79 | MAPT (0.48) | PDE5AMEN1KMT2AALDH1A1CLK4 | |
| SCHEMBL3341706 | 0.79 | ESR1 (0.50) | PDE5ASMN1; SMN2CLK4 | |
| SCHEMBL3340533 | 0.79 | RAB9A (0.49) | PDE5ASMN1; SMN2 | |
| SCHEMBL5119670 | 0.78 | HIF1A (0.46) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5121170 | 0.78 | TSHR (0.44) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | PDE5A 3608/4885MEN1 2315/4885KMT2A 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.